<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11679969</article-id><article-id pub-id-type="doi">10.3390/ph17121726</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-17-01726</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Interaction of Histamine H<sub>3</sub> and Dopamine D<sub>1</sub> Receptors on Hyperkinetic Alterations in Animal Models of Parkinson&#x02019;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Avila-Luna</surname><given-names>Alberto</given-names></name><xref rid="af1-pharmaceuticals-17-01726" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Verduzco-Mendoza</surname><given-names>Antonio</given-names></name><xref rid="af2-pharmaceuticals-17-01726" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Olmos-Hern&#x000e1;ndez</surname><given-names>Adriana</given-names></name><xref rid="af2-pharmaceuticals-17-01726" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Cortes-Altamirano</surname><given-names>Jos&#x000e9; Luis</given-names></name><xref rid="af1-pharmaceuticals-17-01726" ref-type="aff">1</xref><xref rid="af3-pharmaceuticals-17-01726" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Alfaro-Rodr&#x000ed;guez</surname><given-names>Alfonso</given-names></name><xref rid="af1-pharmaceuticals-17-01726" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0791-8397</contrib-id><name><surname>Arias-Monta&#x000f1;o</surname><given-names>Jos&#x000e9;-Antonio</given-names></name><xref rid="af4-pharmaceuticals-17-01726" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Bueno-Nava</surname><given-names>Antonio</given-names></name><xref rid="af1-pharmaceuticals-17-01726" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-17-01726" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Quaglia</surname><given-names>Wilma</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Del Bello</surname><given-names>Fabio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-17-01726"><label>1</label>Divisi&#x000f3;n de Neurociencias B&#x000e1;sicas, Instituto Nacional de Rehabilitaci&#x000f3;n Luis Guillermo Ibarra Ibarra, SSa, Calzada M&#x000e9;xico-Xochimilco 289, Arenal de Guadalupe, Ciudad de M&#x000e9;xico 14389, Mexico</aff><aff id="af2-pharmaceuticals-17-01726"><label>2</label>Bioterio y Cirug&#x000ed;a Experimental, Instituto Nacional de Rehabilitaci&#x000f3;n Luis Guillermo Ibarra Ibarra, SSa, Calzada M&#x000e9;xico-Xochimilco 289, Arenal de Guadalupe, Ciudad de M&#x000e9;xico 14389, Mexico</aff><aff id="af3-pharmaceuticals-17-01726"><label>3</label>Departamento de Quiropr&#x000e1;ctica, Universidad Estatal del Valle de Ecatepec, Ecatepec de Morelos 55210, Mexico</aff><aff id="af4-pharmaceuticals-17-01726"><label>4</label>Departamento de Fisiolog&#x000ed;a, Biof&#x000ed;sica y Neurociencias, Centro de Investigaci&#x000f3;n y de Estudios Avanzados del Instituto Polit&#x000e9;cnico Nacional, Av. IPN 2508, Zacatenco, Ciudad de M&#x000e9;xico 07360, Mexico</aff><author-notes><corresp id="c1-pharmaceuticals-17-01726"><label>*</label>Correspondence: <email>abueno@inr.gob.mx</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>17</volume><issue>12</issue><elocation-id>1726</elocation-id><history><date date-type="received"><day>23</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>12</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Parkinson&#x02019;s disease is associated with the loss of more than 40% of dopaminergic neurons in the substantia nigra pars compacta. One of the therapeutic options for restoring striatal dopamine levels is the administration of L-3,4-dihydroxyphenylalanine (L-Dopa). However, Parkinson&#x02019;s disease patients on long-term L-Dopa therapy often experience motor complications, such as dyskinesias. L-Dopa-induced dyskinesias (LIDs) manifest as abnormal involuntary movements and are produced by elevated striatal dopamine levels, which lead to increased activity of the basal ganglia direct striato-nigral pathway. Dopamine D<sub>1</sub> receptors are more than 95% confined to neurons of the direct pathway, where they colocalize with histamine H<sub>3</sub> receptors. There is evidence of functional interactions between D<sub>1</sub> and H<sub>3</sub> receptors, and here we review the consequences of these interactions on LIDs.</p></abstract><kwd-group><kwd>dopamine</kwd><kwd>histamine</kwd><kwd>D<sub>1</sub> receptor</kwd><kwd>H<sub>3</sub> receptor</kwd><kwd>L-Dopa-induced dyskinesias</kwd><kwd>striatum</kwd><kwd>cerebral cortex</kwd><kwd>Parkinson&#x02019;s disease</kwd><kwd>GABA</kwd><kwd>glutamate</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-17-01726"><title>1. Introduction</title><p>Parkinson&#x02019;s disease (PD) is one of the most common neurodegenerative disorders worldwide, only second to Alzheimer&#x02019;s disease. PD has a prevalence of more than 6 million people [<xref rid="B1-pharmaceuticals-17-01726" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-17-01726" ref-type="bibr">2</xref>] and is originated by the progressive loss of the dopaminergic neurons located in the substantia nigra <italic toggle="yes">pars compacta</italic> (SNc) [<xref rid="B1-pharmaceuticals-17-01726" ref-type="bibr">1</xref>,<xref rid="B3-pharmaceuticals-17-01726" ref-type="bibr">3</xref>]. The administration of L-3,4-dihydroxyphenylalanine (L-Dopa) is one of the most effective treatments for PD motor symptoms [<xref rid="B2-pharmaceuticals-17-01726" ref-type="bibr">2</xref>,<xref rid="B4-pharmaceuticals-17-01726" ref-type="bibr">4</xref>]. However, in the long term, L-Dopa administration induces abnormal involuntary movements (AIMs), known as L-Dopa-induced dyskinesias (LIDs) [<xref rid="B5-pharmaceuticals-17-01726" ref-type="bibr">5</xref>].</p><p>LIDs are associated with elevated dopamine (DA) levels in the nucleus striatum, which lead to molecular and cellular alterations in the function of the basal ganglia (BG) direct pathway (see below and <xref rid="pharmaceuticals-17-01726-f001" ref-type="fig">Figure 1</xref>C) [<xref rid="B4-pharmaceuticals-17-01726" ref-type="bibr">4</xref>,<xref rid="B6-pharmaceuticals-17-01726" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-17-01726" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-17-01726" ref-type="bibr">8</xref>]. The post-synaptic changes include cellular redistribution of DA D<sub>1</sub>-like receptors (D<sub>1</sub>Rs), sensitization of D<sub>1</sub>R intracellular signaling, and abnormal gene expression in D<sub>1</sub>R-expressing neurons [<xref rid="B4-pharmaceuticals-17-01726" ref-type="bibr">4</xref>,<xref rid="B9-pharmaceuticals-17-01726" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-17-01726" ref-type="bibr">10</xref>].</p><p>In LIDs, the hyperactivity of the direct BG pathway is critical for the observed hypoactivity of the GABAergic pallido/nigro-thalamic projections, resulting from increased activity of the glutamatergic thalamo-cortical pathway (<xref rid="pharmaceuticals-17-01726-f001" ref-type="fig">Figure 1</xref>C) [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-17-01726" ref-type="bibr">12</xref>]. Amantadine is highly effective for treating LIDs by antagonizing glutamate receptors and reducing excitatory neurotransmission [<xref rid="B2-pharmaceuticals-17-01726" ref-type="bibr">2</xref>,<xref rid="B13-pharmaceuticals-17-01726" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-17-01726" ref-type="bibr">14</xref>]. However, the withdrawal of amantadine aggravates LIDs after ~7 days, indicating action reversibility and a rebound effect [<xref rid="B15-pharmaceuticals-17-01726" ref-type="bibr">15</xref>].</p><p>The BG direct and indirect pathways are initiated by the projecting axons of the striatal GABAergic medium spiny neurons (MSNs), which constitute 95% of the striatal neuronal population [<xref rid="B16-pharmaceuticals-17-01726" ref-type="bibr">16</xref>]. The striatum is innervated by axons of dopaminergic and histaminergic neurons located in the SNc and the hypothalamus tuberomammillary nucleus, respectively [<xref rid="B16-pharmaceuticals-17-01726" ref-type="bibr">16</xref>]. Histamine H<sub>3</sub> receptors (H<sub>3</sub>Rs) are co-expressed with D<sub>1</sub>Rs in the MSNs of the BG striato-nigral or direct pathway and with D<sub>2</sub>-like receptors (D<sub>2</sub>Rs) in striato-pallidal MSNs that originate from the first segment of the indirect pathway [<xref rid="B17-pharmaceuticals-17-01726" ref-type="bibr">17</xref>].</p><p>D<sub>1</sub>Rs comprise the D<sub>1</sub> and D<sub>5</sub> subtypes, both coupled to G&#x003b1;<sub>s</sub> proteins and thus to the activation of the cAMP/protein kinase A (PKA) signaling pathway. D<sub>2</sub>Rs include the D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> subtypes, all coupled to G&#x003b1;<sub>i/o</sub> proteins. The D<sub>2</sub>R main signaling mechanisms include the inhibition of the cAMP/PKA pathway and reduction in calcium entry through voltage-activated Ca<sup>2+</sup> channels involved in neurotransmitter release [<xref rid="B18-pharmaceuticals-17-01726" ref-type="bibr">18</xref>].</p><p>H<sub>3</sub>Rs couple to G&#x003b1;<sub>i/o</sub> proteins, and both the G&#x003b1;<sub>i/o</sub> subunits and the G&#x003b2;&#x003b3; dimers mediate G protein-dependent signaling. The actions reported are: (a) inhibition of cAMP formation; (b) inhibition of the Na<sup>+</sup>/H<sup>+</sup> exchanger; (c) inhibition of N- and P/Q-type voltage-gated Ca<sup>2+</sup> channels; (d) activation of G protein-gated inwardly rectifying K<sup>+</sup> channels (GIRKs); (e) phospholipase C (PLC) activation; (f) activation of the mitogen-activated kinase (MAPK) pathway; (g) activation of the phosphatidylinositol 3-kinase (PI3K) pathway; and h) phospholipase A<sub>2</sub> (PLA<sub>2</sub>) activation [<xref rid="B19-pharmaceuticals-17-01726" ref-type="bibr">19</xref>].</p><p>As indicated above, MSNs of the BG direct pathway co-express H<sub>3</sub>Rs and D<sub>1</sub>Rs [<xref rid="B17-pharmaceuticals-17-01726" ref-type="bibr">17</xref>], and in slices of rat substantia nigra <italic toggle="yes">pars reticulata</italic> (SNr) and striatum H<sub>3</sub>R activation inhibits D<sub>1</sub>R-stimulated cAMP accumulation and GABA release [<xref rid="B20-pharmaceuticals-17-01726" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-17-01726" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-17-01726" ref-type="bibr">22</xref>], indicating an opposite functional interaction. However, there is still limited information on whether this functional interaction affects LIDs, originating from molecular and cellular changes in the BG circuitry, with D<sub>1</sub>R overstimulation playing a causative role. In this review, we examine the reported effects of co-activating D<sub>1</sub>Rs and H<sub>3</sub>Rs on BG function and their potential influence on LIDs.</p></sec><sec id="sec2-pharmaceuticals-17-01726"><title>2. Striatal Synaptic Circuitry</title><p>The striatum is the main target of the BG synaptic afferents and receives two major glutamatergic inputs, the first from all areas of the cerebral cortex [<xref rid="B23-pharmaceuticals-17-01726" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-17-01726" ref-type="bibr">24</xref>] and the second from the thalamus [<xref rid="B25-pharmaceuticals-17-01726" ref-type="bibr">25</xref>] (see <xref rid="pharmaceuticals-17-01726-f001" ref-type="fig">Figure 1</xref>A). The number of synaptic contacts of cortical afferents with MSNs nearly equals that of the thalamic inputs [<xref rid="B23-pharmaceuticals-17-01726" ref-type="bibr">23</xref>,<xref rid="B25-pharmaceuticals-17-01726" ref-type="bibr">25</xref>]; however, in terms of synaptic interactions and functional properties, the cortico-striatal projections are highly dominant [<xref rid="B25-pharmaceuticals-17-01726" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-17-01726" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-17-01726" ref-type="bibr">27</xref>]. The striatum also receives glutamatergic inputs from other brain regions, namely the subthalamic nucleus (STN), the pedunculopontine nucleus, the amygdala, and the hippocampus [<xref rid="B28-pharmaceuticals-17-01726" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-17-01726" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-17-01726" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-17-01726" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-17-01726" ref-type="bibr">32</xref>].</p><p>The external segment of the external globus pallidus (GPe) is a GABAergic nucleus that receives massive synaptic inputs from the striatal MSNs and provides GABAergic projections to the STN and back to the striatum [<xref rid="B16-pharmaceuticals-17-01726" ref-type="bibr">16</xref>,<xref rid="B33-pharmaceuticals-17-01726" ref-type="bibr">33</xref>]. Other neurons in the striatal circuit include GABAergic and cholinergic interneurons, which represent almost 5% of all striatal neurons in rodents and up to 23% in primates [<xref rid="B16-pharmaceuticals-17-01726" ref-type="bibr">16</xref>].</p><p>The striatum thus integrates diverse synaptic inputs, predominantly glutamatergic information from the cerebral cortex and thalamus and dopaminergic input from the SNc. In turn, through the direct and indirect pathways, the striatum modulates the function of the BG output nuclei, namely SNr and the globus pallidus internal segment (GPi) in primates and humans or entopeduncular nucleus in rodents. In recent decades, it has been clear that histaminergic innervation (see <xref rid="pharmaceuticals-17-01726-f001" ref-type="fig">Figure 1</xref>A) [<xref rid="B16-pharmaceuticals-17-01726" ref-type="bibr">16</xref>,<xref rid="B34-pharmaceuticals-17-01726" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-17-01726" ref-type="bibr">35</xref>] also plays a relevant role in modulating the striatal function, thus contributing to the intricate regulatory mechanisms involved in motor control, cognition, and neuropsychiatric conditions [<xref rid="B34-pharmaceuticals-17-01726" ref-type="bibr">34</xref>,<xref rid="B36-pharmaceuticals-17-01726" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-17-01726" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-17-01726" ref-type="bibr">38</xref>].</p></sec><sec id="sec3-pharmaceuticals-17-01726"><title>3. Distribution of D<sub>1</sub>Rs and H<sub>3</sub>Rs in the Striatum</title><p>H<sub>3</sub>Rs are localized on histaminergic terminals as autoreceptors controlling histamine synthesis and release [<xref rid="B19-pharmaceuticals-17-01726" ref-type="bibr">19</xref>]. In the striatum, H<sub>3</sub>Rs are co-expressed by D<sub>1</sub>Rs in the MSNs of the direct BG pathway [<xref rid="B17-pharmaceuticals-17-01726" ref-type="bibr">17</xref>,<xref rid="B39-pharmaceuticals-17-01726" ref-type="bibr">39</xref>] and with D<sub>2</sub> receptors (D<sub>2</sub>Rs) in MSNs of the indirect pathway [<xref rid="B40-pharmaceuticals-17-01726" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-17-01726" ref-type="bibr">41</xref>]. In both MSN subpopulations, H<sub>3</sub>Rs are located in the somato-dendritic region and in axons that project to the GPe for the indirect pathway, and for the direct pathway on the soma and nerve terminals of MSNs that project to the output nuclei of the BG (SNr and GPi) [<xref rid="B42-pharmaceuticals-17-01726" ref-type="bibr">42</xref>]. They are also present in MSN collateral axons that innervate MSNs of the same or different subpopulations (see <xref rid="pharmaceuticals-17-01726-f001" ref-type="fig">Figure 1</xref>A) [<xref rid="B43-pharmaceuticals-17-01726" ref-type="bibr">43</xref>].</p><p>In addition, H<sub>3</sub>Rs are located on striatal glutamatergic and dopaminergic afferents from the cerebral cortex and SNc, respectively, as well as in intrinsic interneurons [<xref rid="B17-pharmaceuticals-17-01726" ref-type="bibr">17</xref>]. For cholinergic interneurons, the expression of H<sub>3</sub>R mRNA was confirmed in both the ventral (nucleus accumbens) and dorsal striatum [<xref rid="B44-pharmaceuticals-17-01726" ref-type="bibr">44</xref>]. However, H<sub>3</sub>R activation hyperpolarizes the resting membrane potential and decreases the spontaneous firing rate of cholinergic interneurons in the nucleus accumbens but not in the striatum. Furthermore, the lack of effect of H<sub>3</sub>R activation on acetylcholine release from nucleus accumbens synaptosomes suggests a trans-synaptic mechanism involving reduced acetylcholine release, mediated by somatodendritic H<sub>3</sub>Rs, which leads to decreased activation of nicotinic receptors located on dopaminergic terminals [<xref rid="B44-pharmaceuticals-17-01726" ref-type="bibr">44</xref>].</p><p>Striatal interneurons also express dopamine receptors. Functionally, D<sub>1</sub>R activation depolarizes GABAergic low-threshold spike (LTS) interneurons and results in excitatory post-synaptic currents (EPSCs) in cholinergic and fast-spiking (FSI) GABAergic interneurons. D<sub>2</sub>R activation induces inhibitory post-synaptic currents (IPSCs) in cholinergic interneurons [<xref rid="B45-pharmaceuticals-17-01726" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-17-01726" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-17-01726" ref-type="bibr">47</xref>]. Thus, a functional interaction between H<sub>3</sub>Rs and D<sub>1</sub>Rs can also occur in striatal cholinergic and GABAergic interneurons.</p><p>Altogether, this information indicates that via H<sub>3</sub>R activation, histamine modulates key striatal synaptic pathways, influencing histaminergic, glutamatergic, and dopaminergic inputs to MSNs and striatal interneurons.</p></sec><sec id="sec4-pharmaceuticals-17-01726"><title>4. Functional Interaction Between H<sub>3</sub>Rs and D<sub>1</sub>Rs in the Striato-Nigral MSNs</title><p>There is information that supports the functional interaction between H<sub>3</sub>Rs and D<sub>1</sub>Rs in striato-nigral MSNs and, thus, in the direct BG pathway.</p><p>The first evidence for this interaction was the report that in slices of rat striatum and SNr, D<sub>1</sub>R activation facilitated depolarization-evoked GABA release, and H<sub>3</sub>R activation by the selective agonist immepip inhibited the component of release due to D<sub>1</sub>R stimulation [<xref rid="B20-pharmaceuticals-17-01726" ref-type="bibr">20</xref>,<xref rid="B22-pharmaceuticals-17-01726" ref-type="bibr">22</xref>]. Also in striatal slices, H<sub>3</sub>R activation inhibited D<sub>1</sub>R-induced cAMP accumulation, an action likely to take place in MSN bodies and their collaterals [<xref rid="B21-pharmaceuticals-17-01726" ref-type="bibr">21</xref>].</p><p>Further evaluation showed that the facilitatory action of D<sub>1</sub>Rs was mimicked by 8-bromo-cyclic AMP, prevented by PKA inhibition, and markedly reduced by &#x003c9;-agatoxin TK, a blocker of P/Q-type voltage-gated Ca<sup>2+</sup> channels, but not by &#x003c9;-conotoxin MVIIA or nimodipine (blockers of N- or L-type Ca<sup>2+</sup> channels, respectively). Moreover, the effect of 8-bromo-cyclic AMP was practically abolished by H<sub>3</sub>R activation [<xref rid="B48-pharmaceuticals-17-01726" ref-type="bibr">48</xref>]. Together, these data indicate that D<sub>1</sub>R-induced facilitation and H<sub>3</sub>R-mediated inhibition of GABA release from D<sub>1</sub>-MSN axon terminals converge at voltage-activated P-/Q-type Ca<sup>2+</sup> channels present in the striato-nigral axons and the collaterals of D<sub>1</sub>R-expressing MSNs that remain in the striatum.</p><p>One heterodimeric configuration between D<sub>1</sub>Rs and H<sub>3</sub>Rs was confirmed on striato-nigral MSNs, where D<sub>1</sub>R activation facilitates the H<sub>3</sub>R-mediated stimulation of mitogen-activated protein kinases (MAPKs) in striatal slices [<xref rid="B49-pharmaceuticals-17-01726" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-17-01726" ref-type="bibr">50</xref>]. This effect was not found in striato-pallidal MSNs [<xref rid="B50-pharmaceuticals-17-01726" ref-type="bibr">50</xref>]. Furthermore, H<sub>3</sub>Rs can form heteroreceptor complexes with D<sub>1</sub>Rs and glutamate N-methyl-D-aspartate (NMDA) receptors. In the D<sub>1</sub>R/H<sub>3</sub>R dimer, H<sub>3</sub>R activation reduces D<sub>1</sub>R affinity for selective agonists and shifts D<sub>1</sub>R coupling from G&#x003b1;<sub>s</sub> to G&#x003b1;<sub>i/o</sub> proteins [<xref rid="B49-pharmaceuticals-17-01726" ref-type="bibr">49</xref>,<xref rid="B51-pharmaceuticals-17-01726" ref-type="bibr">51</xref>], and in the D<sub>1</sub>R/H<sub>3</sub>R/NMDA receptor complex, H<sub>3</sub>R activation prevents D<sub>1</sub>R-induced ERK-1/2 phosphorylation [<xref rid="B52-pharmaceuticals-17-01726" ref-type="bibr">52</xref>].</p><p>In the same line, by using microdialysis, we reported an in vivo functional interaction between H<sub>3</sub>Rs and D<sub>1</sub>Rs, in which striatal DA efflux is reduced by the intra-striatal infusion of the D<sub>1</sub>R agonist SKF-38393, an effect counteracted by the co-infusion of the H<sub>3</sub>R agonist immepip [<xref rid="B53-pharmaceuticals-17-01726" ref-type="bibr">53</xref>]. This result indicates that the histaminergic system participates in a negative feedback mechanism that controls dopaminergic transmission in the striatum and involves post-synaptic D<sub>1</sub>Rs and D<sub>2</sub>Rs as well as pre-synaptic D<sub>2</sub>Rs.</p><p>In conclusion, H<sub>3</sub>Rs and D<sub>1</sub>Rs interact in striato-nigral MSNs, modulating GABA release, the cAMP/PKA signaling pathway, and voltage-activated Ca<sup>2</sup>&#x0207a; channels. The H<sub>3</sub>R-D<sub>1</sub>R functional interaction also contributes to a feedback mechanism that controls striatal neurotransmission, and through heteroreceptor complexes, H<sub>3</sub>Rs and D<sub>1</sub>Rs regulate dopaminergic signaling in the striatum.</p></sec><sec id="sec5-pharmaceuticals-17-01726"><title>5. Functional Interaction Between H<sub>3</sub>Rs and D<sub>1</sub>Rs and Its Effect on Movement</title><p>It is well established that the chronic administration of L-Dopa in PD patients and animals lesioned with neurotoxins (6-OHDA or MPTP) will lead to dyskinesias [<xref rid="B4-pharmaceuticals-17-01726" ref-type="bibr">4</xref>,<xref rid="B7-pharmaceuticals-17-01726" ref-type="bibr">7</xref>,<xref rid="B9-pharmaceuticals-17-01726" ref-type="bibr">9</xref>]. A causal factor of LIDs is the development of D<sub>1</sub>R sensitization in the striatum, with receptors responding atypically to the administration of dopaminergic drugs [<xref rid="B4-pharmaceuticals-17-01726" ref-type="bibr">4</xref>]. The experimental evidence previously reviewed suggested a role for the functional interaction between H<sub>3</sub>Rs and D<sub>1</sub>Rs in the control of movement. In this line, the pioneer study by Papathanou et al. [<xref rid="B54-pharmaceuticals-17-01726" ref-type="bibr">54</xref>] showed that the systemic administration of a single dose of the H<sub>3</sub>R agonist immepip at 1, 5, or 10 mg/kg did not affect LIDs in rats lesioned with 6-hydroxydopamine (6-OHDA) in the SNc [<xref rid="B53-pharmaceuticals-17-01726" ref-type="bibr">53</xref>]. However, the study was not concluded for marmosets lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and primed with L-Dopa because the administration of immepip or imetit, also H<sub>3</sub>R agonist, resulted in adverse effects that lead to interrupting the experiments. Nevertheless, partial data from the study showed that both agonists reduced the antiparkinsonian response induced by L-Dopa, thus appearing to decrease LIDs [<xref rid="B54-pharmaceuticals-17-01726" ref-type="bibr">54</xref>].</p><p>Our results showed that in 6-OHDA-lesioned rats, the chronic administration of the H<sub>3</sub>R agonist immepip in conjunction with L-Dopa reduced abnormal involuntary movement (AIM) scores and total AIMs for the three subtypes analyzed (axial, limb, and orolingual; see <xref rid="pharmaceuticals-17-01726-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B37-pharmaceuticals-17-01726" ref-type="bibr">37</xref>]. In contrast, the subacute and acute administration of a single dose (1 mg/kg, i.p.) of the H<sub>3</sub>R agonist did not affect LIDs, as previously reported by Papathanou et al. [<xref rid="B54-pharmaceuticals-17-01726" ref-type="bibr">54</xref>]. In both studies, at this dose, immepip did not produce any side effects [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>,<xref rid="B37-pharmaceuticals-17-01726" ref-type="bibr">37</xref>]. Differences with the Papathanou et al. study [<xref rid="B54-pharmaceuticals-17-01726" ref-type="bibr">54</xref>] were the supplier of the H<sub>3</sub>R agonist and the administration route (subcutaneous in Papathanou et al. and intraperitoneal in our study).</p><p>Our results suggested thus that the H<sub>3</sub>R agonist helped prevent the development of LIDs but also that immepip is ineffective once dyskinesias are present [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>]. This implication was supported by AIM reappearance after the withdrawal of the H<sub>3</sub>R agonist (see <xref rid="pharmaceuticals-17-01726-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>,<xref rid="B37-pharmaceuticals-17-01726" ref-type="bibr">37</xref>]. Also, the administration of the H<sub>3</sub>R agonist alone for 5 consecutive days prior to L-Dopa did not reduce AIMs [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>], an effect possibly associated with H<sub>3</sub>R desensitization [<xref rid="B55-pharmaceuticals-17-01726" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-17-01726" ref-type="bibr">56</xref>]. In this context, our data show that chronic H<sub>3</sub>R activation along with L-Dopa administration is necessary, in line with the information that a single dose of H<sub>3</sub>R agonists was not sufficient to inhibit LIDs in rats chronically treated with L-Dopa [<xref rid="B54-pharmaceuticals-17-01726" ref-type="bibr">54</xref>].</p><p>In summary, the evidence discussed indicates that H<sub>3</sub>R agonists modulate LIDs by reducing abnormal involuntary movements when chronically administered along L-Dopa. However, acute or subacute administration of H<sub>3</sub>R agonists is ineffective against established LIDs, likely due to H<sub>3</sub>R desensitization.</p></sec><sec id="sec6-pharmaceuticals-17-01726"><title>6. Functional Interaction Between H<sub>3</sub>Rs and D<sub>1</sub>Rs: A Potential Target to Reduce Dyskinesias</title><p>Together, the previously mentioned data raise the question of whether the functional interaction between H<sub>3</sub>Rs and D<sub>1</sub>Rs can be demonstrated in an altered striato-nigral circuit, such as in LIDs in PD.</p><p>As mentioned above, H<sub>3</sub>Rs and D<sub>1</sub>Rs couple to G&#x003b1;<sub>i/o</sub> and G&#x003b1;<sub>s</sub> proteins, respectively, and that H<sub>3</sub>R co-activation reduces D<sub>1</sub>R-induced GABA release and cAMP accumulation in striatal and SNr slices, indicating pre-synaptic and post-synaptic interactions taking place in the MSNs of the direct pathway [<xref rid="B20-pharmaceuticals-17-01726" ref-type="bibr">20</xref>,<xref rid="B22-pharmaceuticals-17-01726" ref-type="bibr">22</xref>,<xref rid="B57-pharmaceuticals-17-01726" ref-type="bibr">57</xref>].</p><p>In studies in which GABA release was analyzed in vivo by HPLC-coupled microdialysis in the rat striatum and total GABA content was determined post-mortem in striatal homogenates, our results showed that the systemic administration of L-Dopa to dyskinetic rats acutely increases GABA levels in striatal dialysates. The GABA/glutamate ratio is an indirect indicator of the fraction of glutamate converted to GABA before release into the synaptic cleft [<xref rid="B58-pharmaceuticals-17-01726" ref-type="bibr">58</xref>], and L-Dopa administration for 21 days augmented both GABA content and the GABA/glutamate ratio in the striatum ipsilateral to the lesioned SNc [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>,<xref rid="B37-pharmaceuticals-17-01726" ref-type="bibr">37</xref>].</p><p>The reported changes in striatal GABAergic transmission suggest overactivity of the MSNs of the direct pathway, and in D<sub>1</sub>R knockout animals with 6-OHDA-induced nigro-striatal denervation, L-Dopa administration does not produce LIDs, ruling out the participation of the D<sub>2</sub>Rs in the genesis of the motor disorder [<xref rid="B59-pharmaceuticals-17-01726" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceuticals-17-01726" ref-type="bibr">60</xref>]. Furthermore, L-Dopa administration for 21 days to parkinsonian animals increases glutamate and GABA levels in the ipsilateral and contralateral cerebral cortices [<xref rid="B37-pharmaceuticals-17-01726" ref-type="bibr">37</xref>]. Together, this information supports the theory that chronic L-Dopa administration to parkinsonian animals increases the activity of the cerebral cortex and striatal MSNs that express D<sub>1</sub>Rs and form the BG direct pathway.</p><p>In the striatum of parkinsonian rats treated with L-Dopa, the increase in both GABA and glutamate levels in dialysates was counteracted by the chronic co-administration of the H<sub>3</sub>R agonist immepip, but not by subchronic or acute administration [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>]. For LIDs, the increase in striatal glutamate and GABA levels is consistent with the enhancement in glutamatergic and GABAergic transmission reported previously [<xref rid="B61-pharmaceuticals-17-01726" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-17-01726" ref-type="bibr">62</xref>]. One likely explanation is the H<sub>3</sub>R-mediated inhibition of glutamate release from the cortico-striatal and thalamo-striatal terminals (see <xref rid="pharmaceuticals-17-01726-f001" ref-type="fig">Figure 1</xref>D) [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>,<xref rid="B42-pharmaceuticals-17-01726" ref-type="bibr">42</xref>,<xref rid="B63-pharmaceuticals-17-01726" ref-type="bibr">63</xref>], along with the decrease in striatal GABA content associated with the functional interaction between D<sub>1</sub>Rs and H<sub>3</sub>Rs [<xref rid="B11-pharmaceuticals-17-01726" ref-type="bibr">11</xref>,<xref rid="B22-pharmaceuticals-17-01726" ref-type="bibr">22</xref>].</p><p>H<sub>3</sub>R activation leads to the inhibition of adenylyl cyclases (ACs) and the subsequent reduction in cAMP formation (see <xref rid="pharmaceuticals-17-01726-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B42-pharmaceuticals-17-01726" ref-type="bibr">42</xref>], and H<sub>3</sub>R activation inhibits D<sub>1</sub>R-induced cAMP accumulation in striatal slices [<xref rid="B21-pharmaceuticals-17-01726" ref-type="bibr">21</xref>]. L-Dopa administration leads to the enhanced activation of the cAMP/PKA pathway, and in MSNs expressing D<sub>1</sub>Rs, PKA phosphorylates several substrates, including DARPP-32 (DA- and cAMP-regulated phosphoprotein of 32 kDa), extracellular signal-regulated kinases (ERK-1/2), and proteins of the mTORC1 signaling pathway [<xref rid="B4-pharmaceuticals-17-01726" ref-type="bibr">4</xref>,<xref rid="B64-pharmaceuticals-17-01726" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-17-01726" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-17-01726" ref-type="bibr">66</xref>]. These molecular changes have been observed in MSNs of the striato-nigral direct pathway but not in MSNs of the indirect pathway [<xref rid="B65-pharmaceuticals-17-01726" ref-type="bibr">65</xref>]. In line with this, LIDs are reduced when L-Dopa administration is combined with drugs such as the PKA inhibitor Rp-cAMPS [<xref rid="B66-pharmaceuticals-17-01726" ref-type="bibr">66</xref>] or SL327, an ERK phosphorylation inhibitor [<xref rid="B63-pharmaceuticals-17-01726" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceuticals-17-01726" ref-type="bibr">64</xref>]. Therefore, it is likely that the functional interaction between D<sub>1</sub>R and H<sub>3</sub>R explains the reduction in LIDs. However, molecular studies to corroborate this hypothesis are lacking.</p><p>From the reviewed information, it can be inferred that the functional interaction between H<sub>3</sub>Rs and D<sub>1</sub>Rs modulates LIDs by reducing L-Dopa-induced increases in striatal GABA and glutamate levels through H<sub>3</sub>R-mediated inhibition of cAMP/PKA signaling. These findings highlight the potential role of H<sub>3</sub>R activation to counteract the overactivity of the striato-nigral-cortical circuit observed in PD, though molecular studies are required to further explore this mechanism.</p></sec><sec id="sec7-pharmaceuticals-17-01726"><title>7. Interaction Between H<sub>3</sub>Rs and D<sub>2</sub>Rs in the Striato-Pallidal MSNs</title><p>H<sub>3</sub>Rs and D<sub>2</sub>Rs are co-expressed by striato-pallidal MSNs, and a few studies suggest a functional interaction between H<sub>3</sub>Rs and D<sub>2</sub>Rs in the striatum [<xref rid="B67-pharmaceuticals-17-01726" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceuticals-17-01726" ref-type="bibr">68</xref>].</p><p>H<sub>3</sub>Rs and D<sub>2</sub>Rs couple to G&#x003b1;<sub>i/o</sub> proteins, and an additive action on [<sup>35</sup>S]-GTP&#x003b3;S binding to rat striatal membranes was observed following the co-activation of both receptors, a result that can be explained by only a fraction of the G&#x003b1;<sub>i/o</sub> protein pool being activated by each of the two receptors or by the activation by each receptor of different G&#x003b1;<sub>i/o</sub> subunit subtypes (&#x003b1;<sub>i1</sub>, &#x003b1;<sub>i2</sub>, &#x003b1;<sub>i3</sub>, &#x003b1;<sub>oA</sub>, or &#x003b1;<sub>oB</sub>) [<xref rid="B67-pharmaceuticals-17-01726" ref-type="bibr">67</xref>].</p><p>In reserpinized mice, H<sub>3</sub>R activation antagonizes locomotor behavior induced by D<sub>2</sub>R stimulation [<xref rid="B68-pharmaceuticals-17-01726" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceuticals-17-01726" ref-type="bibr">69</xref>]. It was also reported that H<sub>3</sub>R activation reduces D<sub>2</sub>R affinity for the agonist quinpirole in sheep brain membranes and that the human H<sub>3</sub>R and D<sub>2</sub>R form a heterodimer as evidenced by BRET assays in transfected HEK-293 cells [<xref rid="B69-pharmaceuticals-17-01726" ref-type="bibr">69</xref>]. H<sub>3</sub>Rs co-immunoprecipitate with D<sub>2</sub>Rs in rat striatal lysates, and the proximity ligation assay (PLA) in mouse striatal sections supports the formation of an H<sub>3</sub>R/D<sub>2</sub>R complex. Furthermore, H<sub>3</sub>R co-activation modulated D<sub>2</sub>R-mediated Akt&#x02013;GSK3&#x003b2; signaling in mouse D<sub>2</sub>R-expressing MSNs as visualized by immunohistochemistry and Western blot [<xref rid="B68-pharmaceuticals-17-01726" ref-type="bibr">68</xref>].</p><p>Together, this information indicates that H<sub>3</sub>Rs and D<sub>2</sub>Rs interact physically and functionally to modulate the activity of striato-pallidal neurons. However, as mentioned above, in D<sub>1</sub>R-knockout animals with 6-OHDA-induced lesions to striato-nigral neurons, the administration of L-Dopa does not result in dyskinesias, discarding a role for D<sub>2</sub>R in the pathogenesis of the disorder [<xref rid="B57-pharmaceuticals-17-01726" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-17-01726" ref-type="bibr">58</xref>].</p></sec><sec id="sec8-pharmaceuticals-17-01726"><title>8. H<sub>3</sub>R/D<sub>1</sub>R Interaction in Huntington&#x02019;s Disease (HD)</title><p>HD is a motor progressive neurodegenerative disorder caused by the expansion of a cytosine&#x02013;adenine&#x02013;guanine (CAG) trinucleotide repeat, coding a polyglutamine repeat within the N-terminal region of the protein huntingtin [<xref rid="B70-pharmaceuticals-17-01726" ref-type="bibr">70</xref>]. Like LIDs, dyskinesias in HD involve overactivity of the thalamo-cortical circuit. Dysfunction and death of striatal MSNs is a key HD neuropathological hallmark, and alterations in the striatal dopaminergic system may contribute to HD pathophysiology.</p><p>D<sub>1</sub>R over-activation occurs in the initial stages of HD, leading to abnormal dopaminergic neurotransmission and cell death [<xref rid="B71-pharmaceuticals-17-01726" ref-type="bibr">71</xref>]. In the study by Moreno-Delgado et al. [<xref rid="B72-pharmaceuticals-17-01726" ref-type="bibr">72</xref>], D<sub>1</sub>R/H<sub>3</sub>R heteromers were detected in immortalized striatal cells expressing mutant STHdhQ111 huntingtin, and D<sub>1</sub>R-induced ERK-1/2 phosphorylation, increase in intracellular Ca<sup>2+</sup> levels and cell death were prevented by the H<sub>3</sub>R antagonist thioperamide via cross-antagonism. In the mutant HdhQ7/Q111 mouse, an HD model, thioperamide reduced motor and memory deficits. Furthermore, D<sub>1</sub>R/H<sub>3</sub>R heteromers were detected in the striatum (caudate-putamen) from control individuals and low-grade (0, 1, and 2 grades) HD patients but not in samples from high-grade (grades 3 or 4) patients, indicating that D<sub>1</sub>R/H<sub>3</sub>R heteromers are lost at late HD stages.</p><p>These data indicate that D<sub>1</sub>R/H<sub>3</sub>R heteromers participate in HD pathophysiology and may thus represent novel targets for the treatment of the disease.</p></sec><sec sec-type="conclusions" id="sec9-pharmaceuticals-17-01726"><title>9. Conclusions</title><p>The functional interaction between D<sub>1</sub>Rs and H<sub>3</sub>Rs most likely explains the H<sub>3</sub>R-induced reduction of LIDs in parkinsonism models, and may be the basis for novel pharmacological approaches to preventing or treating LIDs in PD patients. However, molecular and pharmacological studies are still required to elucidate in detail the signaling pathways involved in the D<sub>1</sub>R/H<sub>3</sub>R interaction. These findings will contribute to the understanding of the role of D<sub>1</sub>Rs and H<sub>3</sub>Rs in BG dysfunction occurring in hyperkinetic disorders and involving alterations of the dopaminergic system.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Alexander Aguirre P&#x000e9;rez for his technical support in the preparation of the figure related to the behavioral study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.A.-L., J.-A.A.-M., and A.B.-N.; software, A.V.-M., J.L.C.-A., and A.B.-N.; formal analysis, A.V.-M.; data curation, A.V.-M.; writing&#x02014;original draft preparation, A.A.-L., A.V.-M., J.-A.A.-M., and A.B.-N.; writing&#x02014;review and editing, A.O.-H., J.L.C.-A., A.A.-R., and J.-A.A.-M.; visualization, A.V.-M.; supervision, J.-A.A.-M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">6-OHDA</td><td align="left" valign="middle" rowspan="1" colspan="1">6-Hydroxy-dopamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AC</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenylyl cyclase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIMs</td><td align="left" valign="middle" rowspan="1" colspan="1">Abnormal involuntary movements</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BG </td><td align="left" valign="middle" rowspan="1" colspan="1">Basal ganglia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">D<sub>1</sub>Rs</td><td align="left" valign="middle" rowspan="1" colspan="1">Dopamine D<sub>1</sub> receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">D<sub>2</sub>Rs</td><td align="left" valign="middle" rowspan="1" colspan="1">Dopamine D<sub>2</sub> receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DA</td><td align="left" valign="middle" rowspan="1" colspan="1">Dopamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DARPP-32</td><td align="left" valign="middle" rowspan="1" colspan="1">DA- and cAMP-regulated phosphoprotein of 32 kDa</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERK</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular signal-regulated kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPe</td><td align="left" valign="middle" rowspan="1" colspan="1">External segment of the globus pallidus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPi</td><td align="left" valign="middle" rowspan="1" colspan="1">Internal segment of the globus pallidus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H<sub>3</sub>Rs</td><td align="left" valign="middle" rowspan="1" colspan="1">Histamine H<sub>3</sub> receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L-Dopa </td><td align="left" valign="middle" rowspan="1" colspan="1">L-3,4-dihydroxyphenylalanine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LIDs</td><td align="left" valign="middle" rowspan="1" colspan="1">L-Dopa-induced dyskinesias</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPKs</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-activated protein kinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MPTP</td><td align="left" valign="middle" rowspan="1" colspan="1">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MSNs</td><td align="left" valign="middle" rowspan="1" colspan="1">Medium spiny neurons</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD</td><td align="left" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PKA</td><td align="left" valign="middle" rowspan="1" colspan="1">Protein kinase A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNc</td><td align="left" valign="middle" rowspan="1" colspan="1">Substantia nigra <italic toggle="yes">pars compacta</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNr</td><td align="left" valign="middle" rowspan="1" colspan="1">Substantia nigra <italic toggle="yes">pars reticulata</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">STN </td><td align="left" valign="middle" rowspan="1" colspan="1">Subthalamic nucleus</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-17-01726"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tolosa</surname><given-names>E.</given-names></name>
<name><surname>Garrido</surname><given-names>A.</given-names></name>
<name><surname>Scholz</surname><given-names>S.W.</given-names></name>
<name><surname>Poewe</surname><given-names>W.</given-names></name>
</person-group><article-title>Challenges in the diagnosis of Parkinson&#x02019;s disease</article-title><source>Lancet Neurol.</source><year>2021</year><volume>20</volume><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00030-2</pub-id><pub-id pub-id-type="pmid">33894193</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-17-01726"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bloem</surname><given-names>B.R.</given-names></name>
<name><surname>Okun</surname><given-names>M.S.</given-names></name>
<name><surname>Klein</surname><given-names>C.</given-names></name>
</person-group><article-title>Parkinson&#x02019;s disease</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2284</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-17-01726"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ben-Shlomo</surname><given-names>Y.</given-names></name>
<name><surname>Darweesh</surname><given-names>S.</given-names></name>
<name><surname>Llibre-Guerra</surname><given-names>J.</given-names></name>
<name><surname>Marras</surname><given-names>C.</given-names></name>
<name><surname>San Luciano</surname><given-names>M.</given-names></name>
<name><surname>Tanner</surname><given-names>C.</given-names></name>
</person-group><article-title>The epidemiology of Parkinson&#x02019;s disease</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01419-8</pub-id><pub-id pub-id-type="pmid">38245248</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-17-01726"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spigolon</surname><given-names>G.</given-names></name>
<name><surname>Fisone</surname><given-names>G.</given-names></name>
</person-group><article-title>Signal transduction in l-DOPA-induced dyskinesia: From receptor sensitization to abnormal gene expression</article-title><source>J. Neural Transm.</source><year>2018</year><volume>125</volume><fpage>1171</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1007/s00702-018-1847-7</pub-id><pub-id pub-id-type="pmid">29396608</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-17-01726"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Armstrong</surname><given-names>M.J.</given-names></name>
<name><surname>Okun</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Diagnosis and Treatment of Parkinson Disease: A Review</article-title><source>J. Am. Med. Assoc.</source><year>2020</year><volume>323</volume><fpage>548</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.22360</pub-id><pub-id pub-id-type="pmid">32044947</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-17-01726"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pagano</surname><given-names>G.</given-names></name>
<name><surname>Yousaf</surname><given-names>T.</given-names></name>
<name><surname>Politis</surname><given-names>M.</given-names></name>
</person-group><article-title>PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson&#x02019;s Disease</article-title><source>Curr. Neurol. Neurosci. Rep.</source><year>2017</year><volume>17</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1007/s11910-017-0794-2</pub-id><pub-id pub-id-type="pmid">28975571</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-17-01726"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porras</surname><given-names>G.</given-names></name>
<name><surname>De Deurwaerdere</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Marti</surname><given-names>M.</given-names></name>
<name><surname>Morgenstern</surname><given-names>R.</given-names></name>
<name><surname>Sohr</surname><given-names>R.</given-names></name>
<name><surname>Bezard</surname><given-names>E.</given-names></name>
<name><surname>Morari</surname><given-names>M.</given-names></name>
<name><surname>Meissner</surname><given-names>W.G.</given-names></name>
</person-group><article-title>L-dopa-induced dyskinesia: Beyond an excessive dopamine tone in the striatum</article-title><source>Sci. Rep.</source><year>2014</year><volume>4</volume><elocation-id>3730</elocation-id><pub-id pub-id-type="doi">10.1038/srep03730</pub-id><pub-id pub-id-type="pmid">24429495</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-17-01726"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calabresi</surname><given-names>P.</given-names></name>
<name><surname>Picconi</surname><given-names>B.</given-names></name>
<name><surname>Tozzi</surname><given-names>A.</given-names></name>
<name><surname>Ghiglieri</surname><given-names>V.</given-names></name>
<name><surname>Di Filippo</surname><given-names>M.</given-names></name>
</person-group><article-title>Direct and indirect pathways of basal ganglia: A critical reappraisal</article-title><source>Nat. Neurosci.</source><year>2014</year><volume>17</volume><fpage>1022</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1038/nn.3743</pub-id><pub-id pub-id-type="pmid">25065439</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-17-01726"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bastide</surname><given-names>M.F.</given-names></name>
<name><surname>Meissner</surname><given-names>W.G.</given-names></name>
<name><surname>Picconi</surname><given-names>B.</given-names></name>
<name><surname>Fasano</surname><given-names>S.</given-names></name>
<name><surname>Fernagut</surname><given-names>P.O.</given-names></name>
<name><surname>Feyder</surname><given-names>M.</given-names></name>
<name><surname>Francardo</surname><given-names>V.</given-names></name>
<name><surname>Alcacer</surname><given-names>C.</given-names></name>
<name><surname>Ding</surname><given-names>Y.M.</given-names></name>
<name><surname>Brambilla</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson&#x02019;s disease</article-title><source>Prog. Neurobiol.</source><year>2015</year><volume>132</volume><fpage>96</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.07.002</pub-id><pub-id pub-id-type="pmid">26209473</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-17-01726"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berthet</surname><given-names>A.</given-names></name>
<name><surname>Porras</surname><given-names>G.</given-names></name>
<name><surname>Doudnikoff</surname><given-names>E.</given-names></name>
<name><surname>Stark</surname><given-names>H.</given-names></name>
<name><surname>Cador</surname><given-names>M.</given-names></name>
<name><surname>Bezard</surname><given-names>E.</given-names></name>
<name><surname>Bloch</surname><given-names>B.</given-names></name>
</person-group><article-title>Pharmacological Analysis Demonstrates Dramatic Alteration of D-1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L-DOPA-Induced Dyskinesia</article-title><source>J. Neurosci.</source><year>2009</year><volume>29</volume><fpage>4829</fpage><lpage>4835</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5884-08.2009</pub-id><pub-id pub-id-type="pmid">19369551</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-17-01726"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avila-Luna</surname><given-names>A.</given-names></name>
<name><surname>R&#x000ed;os</surname><given-names>C.</given-names></name>
<name><surname>G&#x000e1;lvez-Rosas</surname><given-names>A.</given-names></name>
<name><surname>Montes</surname><given-names>S.</given-names></name>
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.-A.</given-names></name>
<name><surname>Bueno-Nava</surname><given-names>A.</given-names></name>
</person-group><article-title>Chronic administration of the histamine H3 receptor agonist immepip decreases l-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats</article-title><source>Psychopharmacology</source><year>2019</year><volume>236</volume><fpage>1937</fpage><lpage>1948</lpage><pub-id pub-id-type="doi">10.1007/s00213-019-5182-y</pub-id><pub-id pub-id-type="pmid">30762089</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-17-01726"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jimenez-Urbieta</surname><given-names>H.</given-names></name>
<name><surname>Gago</surname><given-names>B.</given-names></name>
<name><surname>de la Riva</surname><given-names>P.</given-names></name>
<name><surname>Delgado-Alvarado</surname><given-names>M.</given-names></name>
<name><surname>Marin</surname><given-names>C.</given-names></name>
<name><surname>Rodriguez-Oroz</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Dyskinesias and impulse control disorders in Parkinson&#x02019;s disease: From pathogenesis to potential therapeutic approaches</article-title><source>Neurosci. Biobehav. Rev.</source><year>2015</year><volume>56</volume><fpage>294</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.07.010</pub-id><pub-id pub-id-type="pmid">26216865</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-17-01726"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<name><surname>Fabbri</surname><given-names>M.</given-names></name>
<name><surname>Poewe</surname><given-names>W.</given-names></name>
</person-group><article-title>Amantadine in the treatment of Parkinson&#x02019;s disease and other movement disorders</article-title><source>Lancet Neurol.</source><year>2021</year><volume>20</volume><fpage>1048</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00249-0</pub-id><pub-id pub-id-type="pmid">34678171</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-17-01726"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalia</surname><given-names>L.V.</given-names></name>
<name><surname>Lang</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Parkinson&#x02019;s disease</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>896</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61393-3</pub-id><pub-id pub-id-type="pmid">25904081</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-17-01726"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jing</surname><given-names>X.-Z.</given-names></name>
<name><surname>Yuan</surname><given-names>X.-Z.</given-names></name>
<name><surname>Luo</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>S.-Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.-P.</given-names></name>
</person-group><article-title>An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson&#x02019;s Disease</article-title><source>Curr. Neuropharmacol.</source><year>2023</year><volume>21</volume><fpage>1806</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.2174/1570159X20666220222150811</pub-id><pub-id pub-id-type="pmid">35193486</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-17-01726"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolam</surname><given-names>J.P.</given-names></name>
<name><surname>Ellender</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Histamine and the striatum</article-title><source>Neuropharmacology</source><year>2016</year><volume>106</volume><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.013</pub-id><pub-id pub-id-type="pmid">26275849</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-17-01726"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Sep&#x000fa;lveda</surname><given-names>M.</given-names></name>
<name><surname>Rosell</surname><given-names>S.</given-names></name>
<name><surname>Hoffmann</surname><given-names>H.M.</given-names></name>
<name><surname>Castillo-Ruiz</surname><given-names>M.d.M.</given-names></name>
<name><surname>Mignon</surname><given-names>V.</given-names></name>
<name><surname>Moreno-Delgado</surname><given-names>D.</given-names></name>
<name><surname>Michel</surname><given-names>V.</given-names></name>
<name><surname>D&#x000ed;az</surname><given-names>J.</given-names></name>
<name><surname>Sabri&#x000e1;</surname><given-names>J.</given-names></name>
<name><surname>Ortiz</surname><given-names>J.</given-names></name>
</person-group><article-title>Cellular distribution of the histamine H<sub>3</sub> receptor in the basal ganglia: Functional modulation of dopamine and glutamate neurotransmission</article-title><source>Basal Ganglia</source><year>2013</year><volume>3</volume><fpage>109</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.baga.2012.12.001</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-17-01726"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beaulieu</surname><given-names>J.M.</given-names></name>
<name><surname>Espinoza</surname><given-names>S.</given-names></name>
<name><surname>Gainetdinov</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Dopamine receptors&#x02014;IUPHAR Review 13</article-title><source>Br. J. Pharmacol.</source><year>2015</year><volume>172</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/bph.12906</pub-id><pub-id pub-id-type="pmid">25671228</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-17-01726"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nieto-Alamilla</surname><given-names>G.</given-names></name>
<name><surname>M&#x000e1;rquez-G&#x000f3;mez</surname><given-names>R.</given-names></name>
<name><surname>Garc&#x000ed;a-G&#x000e1;lvez</surname><given-names>A.-M.</given-names></name>
<name><surname>Morales-Figueroa</surname><given-names>G.-E.</given-names></name>
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.-A.</given-names></name>
</person-group><article-title>The Histamine H<sub>3</sub> Receptor: Structure, Pharmacology, and Function</article-title><source>Mol. Pharmacol.</source><year>2016</year><volume>90</volume><fpage>649</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1124/mol.116.104752</pub-id><pub-id pub-id-type="pmid">27563055</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-17-01726"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>M.</given-names></name>
<name><surname>Floran</surname><given-names>B.</given-names></name>
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.A.</given-names></name>
<name><surname>Young</surname><given-names>J.M.</given-names></name>
<name><surname>Aceves</surname><given-names>J.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> receptor activation selectively inhibits dopamine D<sub>1</sub> receptor-dependent [<sup>3</sup>H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata</article-title><source>Neuroscience</source><year>1997</year><volume>80</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(97)00100-0</pub-id><pub-id pub-id-type="pmid">9252235</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-17-01726"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez-Lemus</surname><given-names>E.</given-names></name>
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> receptor activation inhibits dopamine D<sub>1</sub> receptor-induced cAMP accumulation in rat striatal slices</article-title><source>Neurosci. Lett.</source><year>2004</year><volume>364</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2004.04.045</pub-id><pub-id pub-id-type="pmid">15196671</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-17-01726"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.A.</given-names></name>
<name><surname>Floran</surname><given-names>B.</given-names></name>
<name><surname>Garcia</surname><given-names>M.</given-names></name>
<name><surname>Aceves</surname><given-names>J.</given-names></name>
<name><surname>Young</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> receptor-mediated inhibition of depolarization-induced, dopamine D<sub>1</sub> receptor-dependent release of <sup>3</sup>H-gamma-aminobutryic acid from rat striatal slices</article-title><source>Br. J. Pharmacol.</source><year>2001</year><volume>133</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704053</pub-id><pub-id pub-id-type="pmid">11325806</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-17-01726"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerfen</surname><given-names>C.R.</given-names></name>
<name><surname>Surmeier</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Modulation of Striatal Projection Systems by Dopamine</article-title><source>Annu. Rev. Neurosci.</source><year>2011</year><volume>34</volume><fpage>441</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113641</pub-id><pub-id pub-id-type="pmid">21469956</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-17-01726"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolam</surname><given-names>J.P.</given-names></name>
<name><surname>Hanley</surname><given-names>J.J.</given-names></name>
<name><surname>Booth</surname><given-names>P.A.</given-names></name>
<name><surname>Bevan</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Synaptic organisation of the basal ganglia</article-title><source>J. Anat.</source><year>2000</year><volume>196</volume><issue-part>Pt 4</issue-part><fpage>527</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1046/j.1469-7580.2000.19640527.x</pub-id><pub-id pub-id-type="pmid">10923985</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-17-01726"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Peterson</surname><given-names>J.D.</given-names></name>
<name><surname>Surmeier</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Corticostriatal and thalamostriatal synapses have distinctive properties</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>6483</fpage><lpage>6492</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0435-08.2008</pub-id><pub-id pub-id-type="pmid">18562619</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-17-01726"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silberberg</surname><given-names>G.</given-names></name>
<name><surname>Bolam</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Local and afferent synaptic pathways in the striatal microcircuitry</article-title><source>Curr. Opin. Neurobiol.</source><year>2015</year><volume>33</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2015.05.002</pub-id><pub-id pub-id-type="pmid">26051382</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-17-01726"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>Y.</given-names></name>
<name><surname>Raju</surname><given-names>D.V.</given-names></name>
<name><surname>Pare</surname><given-names>J.F.</given-names></name>
<name><surname>Sidibe</surname><given-names>M.</given-names></name>
</person-group><article-title>The thalamostriatal system: A highly specific network of the basal ganglia circuitry</article-title><source>Trends Neurosci.</source><year>2004</year><volume>27</volume><fpage>520</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2004.07.004</pub-id><pub-id pub-id-type="pmid">15331233</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-17-01726"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>Y.</given-names></name>
<name><surname>Parent</surname><given-names>A.</given-names></name>
</person-group><article-title>Differential connections of caudate nucleus and putamen in the squirrel monkey (<italic toggle="yes">Saimiri sciureus</italic>)</article-title><source>Neuroscience</source><year>1986</year><volume>18</volume><fpage>347</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(86)90159-4</pub-id><pub-id pub-id-type="pmid">3736862</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-17-01726"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doig</surname><given-names>N.M.</given-names></name>
<name><surname>Moss</surname><given-names>J.</given-names></name>
<name><surname>Bolam</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Cortical and Thalamic Innervation of Direct and Indirect Pathway Medium-Sized Spiny Neurons in Mouse Striatum</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>14610</fpage><lpage>14618</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1623-10.2010</pub-id><pub-id pub-id-type="pmid">21048118</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-17-01726"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lodge</surname><given-names>D.J.</given-names></name>
<name><surname>Grace</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia</article-title><source>Trends Pharmacol. Sci.</source><year>2011</year><volume>32</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2011.05.001</pub-id><pub-id pub-id-type="pmid">21700346</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-17-01726"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koshimizu</surname><given-names>Y.</given-names></name>
<name><surname>Fujiyama</surname><given-names>F.</given-names></name>
<name><surname>Nakamura</surname><given-names>K.C.</given-names></name>
<name><surname>Furuta</surname><given-names>T.</given-names></name>
<name><surname>Kaneko</surname><given-names>T.</given-names></name>
</person-group><article-title>Quantitative analysis of axon bouton distribution of subthalamic nucleus neurons in the rat by single neuron visualization with a viral vector</article-title><source>J. Comp. Neurol.</source><year>2013</year><volume>521</volume><fpage>2125</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1002/cne.23277</pub-id><pub-id pub-id-type="pmid">23595816</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-17-01726"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wouterlood</surname><given-names>F.G.</given-names></name>
<name><surname>van Oort</surname><given-names>S.</given-names></name>
<name><surname>Bloemhard</surname><given-names>L.</given-names></name>
<name><surname>Flierman</surname><given-names>N.A.</given-names></name>
<name><surname>Spijkerman</surname><given-names>J.</given-names></name>
<name><surname>Wright</surname><given-names>C.I.</given-names></name>
<name><surname>Beli&#x000eb;n</surname><given-names>J.A.M.</given-names></name>
<name><surname>Groenewegen</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Neurochemical fingerprinting of amygdalostriatal and intra-amygdaloid projections: A tracing&#x02013;immunofluorescence study in the rat</article-title><source>J. Chem. Neuroanat.</source><year>2018</year><volume>94</volume><fpage>154</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2018.11.001</pub-id><pub-id pub-id-type="pmid">30412707</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-17-01726"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kita</surname><given-names>H.</given-names></name>
</person-group><article-title>Globus pallidus external segment</article-title><source>Progress in Brain Research</source><person-group person-group-type="editor">
<name><surname>Tepper</surname><given-names>J.M.</given-names></name>
<name><surname>Abercrombie</surname><given-names>E.D.</given-names></name>
<name><surname>Bolam</surname><given-names>J.P.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2007</year><volume>Volume 160</volume><fpage>111</fpage><lpage>133</lpage></element-citation></ref><ref id="B34-pharmaceuticals-17-01726"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panula</surname><given-names>P.</given-names></name>
<name><surname>Nuutinen</surname><given-names>S.</given-names></name>
</person-group><article-title>The histaminergic network in the brain: Basic organization and role in disease</article-title><source>Nat. Rev. Neurosci.</source><year>2013</year><volume>14</volume><fpage>472</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/nrn3526</pub-id><pub-id pub-id-type="pmid">23783198</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-17-01726"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillot</surname><given-names>C.</given-names></name>
<name><surname>Heron</surname><given-names>A.</given-names></name>
<name><surname>Cochois</surname><given-names>V.</given-names></name>
<name><surname>Tardivel-Lacombe</surname><given-names>J.</given-names></name>
<name><surname>Ligneau</surname><given-names>X.</given-names></name>
<name><surname>Schwartz</surname><given-names>J.C.</given-names></name>
<name><surname>Arrang</surname><given-names>J.M.</given-names></name>
</person-group><article-title>A detailed mapping of the histamine H-3 receptor and its gene transcripts in rat brain</article-title><source>Neuroscience</source><year>2002</year><volume>114</volume><fpage>173</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00135-5</pub-id><pub-id pub-id-type="pmid">12207964</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-17-01726"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sadek</surname><given-names>B.</given-names></name>
<name><surname>Saad</surname><given-names>A.</given-names></name>
<name><surname>Sadeq</surname><given-names>A.</given-names></name>
<name><surname>Jalal</surname><given-names>F.</given-names></name>
<name><surname>Stark</surname><given-names>H.</given-names></name>
</person-group><article-title>Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases</article-title><source>Behav. Brain Res.</source><year>2016</year><volume>312</volume><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2016.06.051</pub-id><pub-id pub-id-type="pmid">27363923</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-17-01726"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avila-Luna</surname><given-names>A.</given-names></name>
<name><surname>G&#x000e1;lvez-Rosas</surname><given-names>A.</given-names></name>
<name><surname>Aguirre-P&#x000e9;rez</surname><given-names>A.</given-names></name>
<name><surname>Hidalgo-Bravo</surname><given-names>A.</given-names></name>
<name><surname>Alfaro-Rodriguez</surname><given-names>A.</given-names></name>
<name><surname>R&#x000ed;os</surname><given-names>C.</given-names></name>
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.-A.</given-names></name>
<name><surname>Bueno-Nava</surname><given-names>A.</given-names></name>
</person-group><article-title>Chronic H<sub>3</sub>R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D<sub>1</sub>R mRNA expression in 6-hydroxydopamine-lesioned male rats</article-title><source>Psychopharmacology</source><year>2023</year><volume>240</volume><fpage>1221</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1007/s00213-023-06339-1</pub-id><pub-id pub-id-type="pmid">37086286</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-17-01726"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rapanelli</surname><given-names>M.</given-names></name>
<name><surname>Pittenger</surname><given-names>C.</given-names></name>
</person-group><article-title>Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions</article-title><source>Neuropharmacology</source><year>2016</year><volume>106</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.019</pub-id><pub-id pub-id-type="pmid">26282120</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-17-01726"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryu</surname><given-names>J.H.</given-names></name>
<name><surname>Yanai</surname><given-names>K.</given-names></name>
<name><surname>Iwata</surname><given-names>R.</given-names></name>
<name><surname>Ido</surname><given-names>T.</given-names></name>
<name><surname>Watanabe</surname><given-names>T.</given-names></name>
</person-group><article-title>Heterogeneous distributions of histamine H3, dopamine D1 and D2 receptors in rat-brain</article-title><source>Neuroreport</source><year>1994</year><volume>5</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1097/00001756-199401000-00022</pub-id><pub-id pub-id-type="pmid">8025257</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-17-01726"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerfen</surname><given-names>C.R.</given-names></name>
<name><surname>Engber</surname><given-names>T.M.</given-names></name>
<name><surname>Mahan</surname><given-names>L.C.</given-names></name>
<name><surname>Susel</surname><given-names>Z.</given-names></name>
<name><surname>Chase</surname><given-names>T.N.</given-names></name>
<name><surname>Monsma</surname><given-names>F.J.</given-names></name>
<name><surname>Sibley</surname><given-names>D.R.</given-names></name>
</person-group><article-title>D<sub>1</sub> and D<sub>2</sub> Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons</article-title><source>Science</source><year>1990</year><volume>250</volume><fpage>1429</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1126/science.2147780</pub-id><pub-id pub-id-type="pmid">2147780</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-17-01726"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Surmeier</surname><given-names>D.J.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Day</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Shen</surname><given-names>W.</given-names></name>
</person-group><article-title>D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons</article-title><source>Trends Neurosci.</source><year>2007</year><volume>30</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2007.03.008</pub-id><pub-id pub-id-type="pmid">17408758</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-17-01726"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rapanelli</surname><given-names>M.</given-names></name>
</person-group><article-title>The magnificent two: Histamine and the H3 receptor as key modulators of striatal circuitry</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><year>2017</year><volume>73</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2016.10.002</pub-id><pub-id pub-id-type="pmid">27773554</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-17-01726"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taverna</surname><given-names>S.</given-names></name>
<name><surname>Ilijic</surname><given-names>E.</given-names></name>
<name><surname>Surmeier</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson&#x02019;s disease</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>5504</fpage><lpage>5512</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5493-07.2008</pub-id><pub-id pub-id-type="pmid">18495884</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-17-01726"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varaschin</surname><given-names>R.K.</given-names></name>
<name><surname>Osterstock</surname><given-names>G.</given-names></name>
<name><surname>Ducrot</surname><given-names>C.</given-names></name>
<name><surname>Leino</surname><given-names>S.</given-names></name>
<name><surname>Bourque</surname><given-names>M.-J.</given-names></name>
<name><surname>Prado</surname><given-names>M.A.M.</given-names></name>
<name><surname>Prado</surname><given-names>V.F.</given-names></name>
<name><surname>Salminen</surname><given-names>O.</given-names></name>
<name><surname>Rannanp&#x000e4;&#x000e4;</surname><given-names>S.</given-names></name>
<name><surname>Trudeau</surname><given-names>L.-E.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons</article-title><source>Neuroscience</source><year>2018</year><volume>376</volume><fpage>188</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2018.01.027</pub-id><pub-id pub-id-type="pmid">29374538</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-17-01726"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kreitzer</surname><given-names>A.C.</given-names></name>
<name><surname>Malenka</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Striatal Plasticity and Basal Ganglia Circuit Function</article-title><source>Neuron</source><year>2008</year><volume>60</volume><fpage>543</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.11.005</pub-id><pub-id pub-id-type="pmid">19038213</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-17-01726"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chuhma</surname><given-names>N.</given-names></name>
<name><surname>Oh</surname><given-names>S.J.</given-names></name>
<name><surname>Rayport</surname><given-names>S.</given-names></name>
</person-group><article-title>The dopamine neuron synaptic map in the striatum</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112204</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112204</pub-id><pub-id pub-id-type="pmid">36867530</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-17-01726"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Centonze</surname><given-names>D.</given-names></name>
<name><surname>Bracci</surname><given-names>E.</given-names></name>
<name><surname>Pisani</surname><given-names>A.</given-names></name>
<name><surname>Gubellini</surname><given-names>P.</given-names></name>
<name><surname>Bernardi</surname><given-names>G.</given-names></name>
<name><surname>Calabresi</surname><given-names>P.</given-names></name>
</person-group><article-title>Activation of dopamine D<sub>1</sub>-like receptors excites LTS interneurons of the striatum</article-title><source>Eur. J. Neurosci.</source><year>2002</year><volume>15</volume><fpage>2049</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.2002.02052.x</pub-id><pub-id pub-id-type="pmid">12099911</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-17-01726"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.A.</given-names></name>
<name><surname>Floran</surname><given-names>B.</given-names></name>
<name><surname>Floran</surname><given-names>L.</given-names></name>
<name><surname>Aceves</surname><given-names>J.</given-names></name>
<name><surname>Young</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Dopamine D<sub>1</sub> receptor facilitation of depolarization-induced release of &#x003b3;-amino-butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels</article-title><source>Synapse</source><year>2007</year><volume>61</volume><fpage>310</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1002/syn.20372</pub-id><pub-id pub-id-type="pmid">17318879</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-17-01726"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Hoffmann</surname><given-names>H.</given-names></name>
<name><surname>Gonzalez-Sepulveda</surname><given-names>M.</given-names></name>
<name><surname>Navarro</surname><given-names>G.</given-names></name>
<name><surname>Casado</surname><given-names>V.</given-names></name>
<name><surname>Cortes</surname><given-names>A.</given-names></name>
<name><surname>Mallol</surname><given-names>J.</given-names></name>
<name><surname>Vignes</surname><given-names>M.</given-names></name>
<name><surname>McCormick</surname><given-names>P.J.</given-names></name>
<name><surname>Canela</surname><given-names>E.I.</given-names></name>
<etal/>
</person-group><article-title>Dopamine D-1-histamine H-3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>5846</fpage><lpage>5854</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.161489</pub-id><pub-id pub-id-type="pmid">21173143</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-17-01726"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rapanelli</surname><given-names>M.</given-names></name>
<name><surname>Frick</surname><given-names>L.R.</given-names></name>
<name><surname>Horn</surname><given-names>K.D.</given-names></name>
<name><surname>Schwarcz</surname><given-names>R.C.</given-names></name>
<name><surname>Pogorelov</surname><given-names>V.</given-names></name>
<name><surname>Nairn</surname><given-names>A.C.</given-names></name>
<name><surname>Pittenger</surname><given-names>C.</given-names></name>
</person-group><article-title>The Histamine H<sub>3</sub> Receptor Differentially Modulates Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral and Striatopallidal Neurons</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>21042</fpage><lpage>21052</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.731406</pub-id><pub-id pub-id-type="pmid">27510032</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-17-01726"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrada</surname><given-names>C.</given-names></name>
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Casado</surname><given-names>V.</given-names></name>
<name><surname>Bongers</surname><given-names>G.</given-names></name>
<name><surname>Cortes</surname><given-names>A.</given-names></name>
<name><surname>Mallol</surname><given-names>J.</given-names></name>
<name><surname>Canela</surname><given-names>E.I.</given-names></name>
<name><surname>Leurs</surname><given-names>R.</given-names></name>
<name><surname>Ferre</surname><given-names>S.</given-names></name>
<name><surname>Lluis</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Marked changes in signal transduction upon heteromerization of dopamine D<sub>1</sub> and histamine H<sub>3</sub> receptors</article-title><source>Br. J. Pharmacol.</source><year>2009</year><volume>157</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00152.x</pub-id><pub-id pub-id-type="pmid">19413572</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-17-01726"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-Ruiz</surname><given-names>M.</given-names></name>
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Moreno-Delgado</surname><given-names>D.</given-names></name>
<name><surname>Navarro</surname><given-names>G.</given-names></name>
<name><surname>Mallol</surname><given-names>J.</given-names></name>
<name><surname>Cortes</surname><given-names>A.</given-names></name>
<name><surname>Lluis</surname><given-names>C.</given-names></name>
<name><surname>Canela</surname><given-names>E.I.</given-names></name>
<name><surname>Casado</surname><given-names>V.</given-names></name>
<name><surname>McCormick</surname><given-names>P.J.</given-names></name>
<etal/>
</person-group><article-title>Heteroreceptor Complexes Formed by Dopamine D<sub>1</sub>, Histamine H<sub>3</sub>, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer&#x02019;s Disease</article-title><source>Mol. Neurobiol.</source><year>2017</year><volume>54</volume><fpage>4537</fpage><lpage>4550</lpage><pub-id pub-id-type="doi">10.1007/s12035-016-9995-y</pub-id><pub-id pub-id-type="pmid">27370794</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-17-01726"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alfaro-Rodr&#x000ed;guez</surname><given-names>A.</given-names></name>
<name><surname>Alonso-Spilsbury</surname><given-names>M.</given-names></name>
<name><surname>Arch-Tirado</surname><given-names>E.</given-names></name>
<name><surname>Gonzalez-Pina</surname><given-names>R.</given-names></name>
<name><surname>Arias-Montano</surname><given-names>J.-A.</given-names></name>
<name><surname>Bueno-Nava</surname><given-names>A.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> receptor activation prevents dopamine D<sub>1</sub> receptor-mediated inhibition of dopamine release in the rat striatum: A microdialysis study</article-title><source>Neurosci. Lett.</source><year>2013</year><volume>552</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.07.026</pub-id><pub-id pub-id-type="pmid">23896530</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-17-01726"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papathanou</surname><given-names>M.</given-names></name>
<name><surname>Jenner</surname><given-names>P.</given-names></name>
<name><surname>Iravani</surname><given-names>M.</given-names></name>
<name><surname>Jackson</surname><given-names>M.</given-names></name>
<name><surname>Stockwell</surname><given-names>K.</given-names></name>
<name><surname>Strang</surname><given-names>I.</given-names></name>
<name><surname>Zeng</surname><given-names>B.-Y.</given-names></name>
<name><surname>McCreary</surname><given-names>A.C.</given-names></name>
<name><surname>Rose</surname><given-names>S.</given-names></name>
</person-group><article-title>The H<sub>3</sub> receptor agonist immepip does not affect <sub>L</sub>-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats</article-title><source>Eur. J. Pharmacol.</source><year>2014</year><volume>741</volume><fpage>304</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.08.004</pub-id><pub-id pub-id-type="pmid">25160743</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-17-01726"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia-Galvez</surname><given-names>A.M.</given-names></name>
<name><surname>Escamilla-Sanchez</surname><given-names>J.</given-names></name>
<name><surname>Flores-Maldonado</surname><given-names>C.</given-names></name>
<name><surname>Contreras</surname><given-names>R.G.</given-names></name>
<name><surname>Arias</surname><given-names>J.M.</given-names></name>
<name><surname>Arias-Montano</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Differential homologous desensitization of the human histamine H<sub>3</sub> receptors of 445 and 365 amino acids expressed in CHO-K1 cells</article-title><source>Neurochem. Int.</source><year>2018</year><volume>112</volume><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2017.11.009</pub-id><pub-id pub-id-type="pmid">29162484</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-17-01726"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osorio-Espinoza</surname><given-names>A.</given-names></name>
<name><surname>Escamilla-Sanchez</surname><given-names>J.</given-names></name>
<name><surname>Aquino-Jarquin</surname><given-names>G.</given-names></name>
<name><surname>Arias-Montano</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Homologous desensitization of human histamine H<sub>3</sub> receptors expressed in CHO-K1 cells</article-title><source>Neuropharmacology</source><year>2014</year><volume>77</volume><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.09.011</pub-id><pub-id pub-id-type="pmid">24161268</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-17-01726"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez-Lemus</surname><given-names>E.</given-names></name>
<name><surname>Arias-Monta&#x000f1;o</surname><given-names>J.-A.</given-names></name>
</person-group><article-title>M<sub>1</sub> Muscarinic Receptors Contribute to, whereas M<sub>4</sub> Receptors Inhibit, Dopamine D<sub>1</sub> Receptor-Induced [<sup>3</sup>H]-Cyclic AMP Accumulation in Rat Striatal Slices</article-title><source>Neurochem. Res.</source><year>2006</year><volume>31</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1007/s11064-006-9052-8</pub-id><pub-id pub-id-type="pmid">16758365</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-17-01726"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000e1;lvez-Rosas</surname><given-names>A.</given-names></name>
<name><surname>Avila-Luna</surname><given-names>A.</given-names></name>
<name><surname>Vald&#x000e9;s-Flores</surname><given-names>M.</given-names></name>
<name><surname>Montes</surname><given-names>S.</given-names></name>
<name><surname>Bueno-Nava</surname><given-names>A.</given-names></name>
</person-group><article-title>GABAergic imbalance is normalized by dopamine D<sub>1</sub> receptor activation in the striatum contralateral to the cortical injury in motor deficit-recovered rats</article-title><source>Psychopharmacology</source><year>2019</year><volume>236</volume><fpage>2211</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.1007/s00213-019-05215-1</pub-id><pub-id pub-id-type="pmid">30859334</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-17-01726"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murer</surname><given-names>M.G.</given-names></name>
<name><surname>Moratalla</surname><given-names>R.</given-names></name>
</person-group><article-title>Striatal signaling in L-DOPA-induced dyskinesia: Common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation</article-title><source>Front. Neuroanat.</source><year>2011</year><volume>5</volume><elocation-id>51</elocation-id><pub-id pub-id-type="doi">10.3389/fnana.2011.00051</pub-id><pub-id pub-id-type="pmid">21886608</pub-id>
</element-citation></ref><ref id="B60-pharmaceuticals-17-01726"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darmopil</surname><given-names>S.</given-names></name>
<name><surname>Martin</surname><given-names>A.B.</given-names></name>
<name><surname>De Diego</surname><given-names>I.R.</given-names></name>
<name><surname>Ares</surname><given-names>S.</given-names></name>
<name><surname>Moratalla</surname><given-names>R.</given-names></name>
</person-group><article-title>Genetic Inactivation of Dopamine D<sub>1</sub> but Not D<sub>2</sub> Receptors Inhibits L-DOPA-Induced Dyskinesia and Histone Activation</article-title><source>Biol. Psychiatry</source><year>2009</year><volume>66</volume><fpage>603</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2009.04.025</pub-id><pub-id pub-id-type="pmid">19520364</pub-id>
</element-citation></ref><ref id="B61-pharmaceuticals-17-01726"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rangel-Barajas</surname><given-names>C.</given-names></name>
<name><surname>Silva</surname><given-names>I.</given-names></name>
<name><surname>Lopez-Santiago</surname><given-names>L.M.</given-names></name>
<name><surname>Aceves</surname><given-names>J.</given-names></name>
<name><surname>Erlij</surname><given-names>D.</given-names></name>
<name><surname>Floran</surname><given-names>B.</given-names></name>
</person-group><article-title><sub>L</sub>-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata</article-title><source>Neurobiol. Dis.</source><year>2011</year><volume>41</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2010.08.018</pub-id><pub-id pub-id-type="pmid">20736067</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-17-01726"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huot</surname><given-names>P.</given-names></name>
<name><surname>Johnston</surname><given-names>T.H.</given-names></name>
<name><surname>Koprich</surname><given-names>J.B.</given-names></name>
<name><surname>Fox</surname><given-names>S.H.</given-names></name>
<name><surname>Brotchie</surname><given-names>J.M.</given-names></name>
</person-group><article-title>The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson&#x02019;s Disease</article-title><source>Pharmacol. Rev.</source><year>2013</year><volume>65</volume><fpage>171</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1124/pr.111.005678</pub-id><pub-id pub-id-type="pmid">23319549</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-17-01726"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Molina-Hernandez</surname><given-names>A.</given-names></name>
<name><surname>Nunez</surname><given-names>A.</given-names></name>
<name><surname>Sierra</surname><given-names>J.J.</given-names></name>
<name><surname>Arias-Montano</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> receptor activation inhibits glutamate release from rat striatal synaptosomes</article-title><source>Neuropharmacology</source><year>2001</year><volume>41</volume><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(01)00144-7</pub-id><pub-id pub-id-type="pmid">11747897</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-17-01726"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santini</surname><given-names>E.</given-names></name>
<name><surname>Valjent</surname><given-names>E.</given-names></name>
<name><surname>Usiello</surname><given-names>A.</given-names></name>
<name><surname>Carta</surname><given-names>M.</given-names></name>
<name><surname>Borgkvist</surname><given-names>A.</given-names></name>
<name><surname>Girault</surname><given-names>J.A.</given-names></name>
<name><surname>Herve</surname><given-names>D.</given-names></name>
<name><surname>Greengard</surname><given-names>P.</given-names></name>
<name><surname>Fisone</surname><given-names>G.</given-names></name>
</person-group><article-title>Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in <sub>L</sub>-DOPA-induced dyskinesia</article-title><source>J. Neurosci.</source><year>2007</year><volume>27</volume><fpage>6995</fpage><lpage>7005</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0852-07.2007</pub-id><pub-id pub-id-type="pmid">17596448</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-17-01726"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santini</surname><given-names>E.</given-names></name>
<name><surname>Alcacer</surname><given-names>C.</given-names></name>
<name><surname>Cacciatore</surname><given-names>S.</given-names></name>
<name><surname>Heiman</surname><given-names>M.</given-names></name>
<name><surname>Herve</surname><given-names>D.</given-names></name>
<name><surname>Greengard</surname><given-names>P.</given-names></name>
<name><surname>Girault</surname><given-names>J.A.</given-names></name>
<name><surname>Valjent</surname><given-names>E.</given-names></name>
<name><surname>Fisone</surname><given-names>G.</given-names></name>
</person-group><article-title><sub>L</sub>-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice</article-title><source>J. Neurochem.</source><year>2009</year><volume>108</volume><fpage>621</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05831.x</pub-id><pub-id pub-id-type="pmid">19187092</pub-id>
</element-citation></ref><ref id="B66-pharmaceuticals-17-01726"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hakansson</surname><given-names>K.</given-names></name>
<name><surname>Lindskog</surname><given-names>M.</given-names></name>
<name><surname>Pozzi</surname><given-names>L.</given-names></name>
<name><surname>Usiello</surname><given-names>A.</given-names></name>
<name><surname>Fisone</surname><given-names>G.</given-names></name>
</person-group><article-title>DARPP-32 and modulation of cAMP signaling: Involvement in motor control and levodopa-induced dyskinesia</article-title><source>Park. Relat. Disord.</source><year>2004</year><volume>10</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2004.02.010</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-17-01726"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Humbert-Claude</surname><given-names>M.</given-names></name>
<name><surname>Morisset</surname><given-names>S.</given-names></name>
<name><surname>Gbahou</surname><given-names>F.</given-names></name>
<name><surname>Arrang</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Histamine H<sub>3</sub> and doparnine D<sub>2</sub> receptor-mediated [<sup>35</sup>S]GTP&#x003b3;[S] binding in rat striatum: Evidence for additive effects but lack of interactions</article-title><source>Biochem. Pharmacol.</source><year>2007</year><volume>73</volume><fpage>1172</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2007.01.006</pub-id><pub-id pub-id-type="pmid">17306767</pub-id>
</element-citation></ref><ref id="B68-pharmaceuticals-17-01726"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Pittenger</surname><given-names>C.</given-names></name>
</person-group><article-title>The histamine H<sub>3</sub> receptor modulates dopamine D<sub>2</sub> receptor&#x02013;dependent signaling pathways and mouse behaviors</article-title><source>J. Biol. Chem.</source><year>2023</year><volume>299</volume><elocation-id>104583</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.104583</pub-id><pub-id pub-id-type="pmid">36871761</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-17-01726"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrada</surname><given-names>C.</given-names></name>
<name><surname>Ferre</surname><given-names>S.</given-names></name>
<name><surname>Casado</surname><given-names>V.</given-names></name>
<name><surname>Cortes</surname><given-names>A.</given-names></name>
<name><surname>Justinova</surname><given-names>Z.</given-names></name>
<name><surname>Barnes</surname><given-names>C.</given-names></name>
<name><surname>Canela</surname><given-names>E.I.</given-names></name>
<name><surname>Goldberg</surname><given-names>S.R.</given-names></name>
<name><surname>Leurs</surname><given-names>R.</given-names></name>
<name><surname>Lluis</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Interactions between histamine H<sub>3</sub> and dopamine D<sub>2</sub> receptors and the implications for striatal function</article-title><source>Neuropharmacology</source><year>2008</year><volume>55</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.05.008</pub-id><pub-id pub-id-type="pmid">18547596</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-17-01726"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roos</surname><given-names>R.A.C.</given-names></name>
</person-group><article-title>Huntington&#x02019;s disease: A clinical review</article-title><source>Orphanet J. Rare Dis.</source><year>2010</year><volume>5</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-5-40</pub-id><pub-id pub-id-type="pmid">21171977</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-17-01726"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>E.</given-names></name>
<name><surname>Cepeda</surname><given-names>C.</given-names></name>
<name><surname>Levine</surname><given-names>M.</given-names></name>
</person-group><article-title>Dopamine imbalance in Huntington&#x02019;s disease: A mechanism for the lack of behavioral flexibility</article-title><source>Front. Neurosci.</source><year>2013</year><volume>7</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2013.00114</pub-id><pub-id pub-id-type="pmid">23847463</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-17-01726"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreno-Delgado</surname><given-names>D.</given-names></name>
<name><surname>Puigdell&#x000ed;vol</surname><given-names>M.</given-names></name>
<name><surname>Moreno</surname><given-names>E.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Ruiz</surname><given-names>M.</given-names></name>
<name><surname>Botta</surname><given-names>J.</given-names></name>
<name><surname>Gasperini</surname><given-names>P.</given-names></name>
<name><surname>Chiarlone</surname><given-names>A.</given-names></name>
<name><surname>Howell</surname><given-names>L.A.</given-names></name>
<name><surname>Scarselli</surname><given-names>M.</given-names></name>
<name><surname>Casad&#x000f3;</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Modulation of dopamine D<sub>1</sub> receptors via histamine H<sub>3</sub> receptors is a novel therapeutic target for Huntington&#x02019;s disease</article-title><source>eLife</source><year>2020</year><volume>9</volume><fpage>e51093</fpage><pub-id pub-id-type="doi">10.7554/eLife.51093</pub-id><pub-id pub-id-type="pmid">32513388</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-17-01726-f001"><label>Figure 1</label><caption><p>Schematic view of the basal ganglia synaptic circuitry. (<bold>A</bold>) Normal circuit; (<bold>B</bold>) parkinsonian circuit; (<bold>C</bold>) dyskinetic circuit, and (<bold>D</bold>) circuit with the antidyskinetic effect of the chronic administration of the H<sub>3</sub>R agonist immepip. Black lines represent inhibitory neuronal pathways, while red lines represent excitatory projections. The thickness of the lines and the color intensity or lightness indicate the degree of activation of each projection. The grey tone in the external segment of the globus pallidus (GPe; 1B), the substantia nigra <italic toggle="yes">pars reticulata</italic> (SNr; 1C), the internal segment of the globus pallidus (GPi; 1C), thalamus (1B), and the subthalamic nucleus (STN; 1C) reflect differences in activation compared to other regions shown in black. Dotted pink lines indicate dopaminergic depletion in the substantia nigra <italic toggle="yes">pars compacta</italic> (SNc). MSN axons project to the SNr and the GPi through a direct pathway and to the GPe, which in turn projects to the STN, forming the indirect pathway that projects to the SNr and GPi. The legends &#x02018;L-Dopa&#x02019; and &#x02018;L-Dopa + immepip&#x02019; for the striatum in panels C and D indicate the systemic administration of L-Dopa alone or in conjunction with the H<sub>3</sub>R agonist immepip, respectively. &#x000bf;?, unconfirmed effect. DA, dopamine; HA, histamine; TMN, tuberomammillary nucleus.</p></caption><graphic xlink:href="pharmaceuticals-17-01726-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01726-f002"><label>Figure 2</label><caption><p>Effect of the systemic administration of the H<sub>3</sub>R agonist immepip (1 mg/kg, i.p.) on total ALO (axial, limb, and orolingual) abnormal involuntary movements (AIMs) induced by L-Dopa (6.25 mg/kg; benserazide 15 mg/kg, i.p.). ALO AIMs were individually counted and then summed per session. The statistical analysis of total AIMs was conducted with repeated-measures ANOVA followed by Bonferroni&#x02019;s post hoc test (8 animals per group). &#x00026;,# <italic toggle="yes">p</italic> &#x0003c; 0.01, compared to the vehicle group; * <italic toggle="yes">p</italic> &#x0003c; 0.001, compared to the L-Dopa group.</p></caption><graphic xlink:href="pharmaceuticals-17-01726-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01726-f003"><label>Figure 3</label><caption><p>Schematic representation of L-Dopa-induced intracellular signaling involving the cAMP/protein kinase A (PKA) pathway (<bold>A</bold>). It is proposed that the co-administration of the H<sub>3</sub>R agonist immepip counteracts the effects of L-Dopa and reduces dyskinesias (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01726-g003" position="float"/></fig></floats-group></article>